8-K: Zimmer Biomet to Acquire Paragon 28 for $1.1 Billion, Expanding Foot and Ankle Portfolio

Zimmer Biomet is set to acquire Paragon 28, a foot and ankle orthopedic company, for an upfront payment of $13.00 per share in cash, plus a contingent value right, in a deal valued at approximately $1.1 billion.

Summary

• Zimmer Biomet has announced a definitive agreement to acquire Paragon 28 for an upfront payment of $13.00 per share in cash.
• The deal corresponds to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion.
• Paragon 28 shareholders will also receive a contingent value right (CVR) entitling them to receive up to $1.00 per share in cash if certain revenue milestones are achieved.
• The CVR will be payable if net sales exceed $346 million up to $361 million during Zimmer Biomet's fiscal year 2026.
• Paragon 28 has announced net revenue for the full year of 2024 to be in a range of $255.9 to $256.2 million, representing 18.2% to 18.4% reported growth over the prior fiscal year.
• Zimmer Biomet expects the proposed transaction to be approximately 3% dilutive to adjusted earnings per share in 2025, about 1% dilutive to 2026 adjusted earnings per share and accretive to adjusted earnings per share within 24 months of deal close.
• The transaction is expected to close in the first half of 2025, subject to regulatory approvals and Paragon 28 stockholder approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The acquisition expands Zimmer Biomet's portfolio into a high-growth area and is expected to be accretive to revenue. However, there are short-term dilution concerns and integration risks.

Positives

• The acquisition strengthens and expands Zimmer Biomet's foot and ankle offerings.
• It complements Zimmer Biomet's global footprint and existing infrastructure.
• The deal accelerates Zimmer Biomet's weighted average market growth rate (WAMGR).
• It expedites penetration opportunities in the fast-growing ambulatory surgery center (ASC) space.
• The acquisition is expected to be immediately accretive to revenue growth.

Negatives

• The transaction is expected to be approximately 3% dilutive to adjusted earnings per share in 2025.
• It is expected to be about 1% dilutive to 2026 adjusted earnings per share.

Risks

• The closing of the transaction is subject to regulatory approvals and Paragon 28 stockholder approval.
• There are risks related to the ability to realize the anticipated benefits of the merger.
• The businesses may not be integrated successfully.
• There are risks relating to the achievement of the revenue milestone necessary for the payment of any contingent value rights.
• The merger could disrupt business and operational relationships.
• The merger could divert management's attention from ongoing business operations.
• There are risks of litigation and regulatory actions related to the merger.

Future Outlook

Zimmer Biomet expects the transaction to be accretive to adjusted earnings per share within 24 months of deal close and expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities.

Management Comments

• Ivan Tornos, President and Chief Executive Officer of Zimmer Biomet, stated that the transaction diversifies Zimmer Biomet's portfolio and positions them well in a high-growth segment.
• Albert DaCosta, Chairman and CEO of Paragon 28, said that joining Zimmer Biomet is an exciting new chapter for Paragon 28 and an incredible opportunity to advance their mission.

Industry Context

This acquisition allows Zimmer Biomet to expand into the high-growth foot and ankle segment, which is estimated to be a ~$5 billion market growing at a high-single-digit rate. It also creates cross-selling opportunities in the rapidly growing ASC space.

Comparison to Industry Standards

• Stryker, Johnson & Johnson (DePuy Synthes), and Medtronic are major competitors in the broader orthopedics market.
• Paragon 28 focuses exclusively on the foot and ankle segment, differentiating it from larger, diversified players.
• The acquisition price reflects the high growth potential and specialized nature of the foot and ankle market.
• The contingent value right structure is a common mechanism in acquisitions to align the interests of the seller with the future performance of the acquired company.

Stakeholder Impact

• Shareholders of Paragon 28 will receive cash and a potential CVR.
• Zimmer Biomet shareholders may experience short-term dilution.
• The acquisition could lead to improved products and services for patients.
• Employees of both companies may experience changes as a result of the integration.

Next Steps

• Paragon 28 will file documents with the SEC, including proxy statements.
• Paragon 28 stockholders will vote on the proposed transaction.
• The companies will seek required regulatory approvals.
• Zimmer Biomet will discuss the expected impacts to 2025 financial results on its upcoming fourth quarter 2024 earnings call.

Key Dates